跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 399 条关于
“bimekizumab-bkz”
全部
399
临床试验
223
药物
91
机构
2
资讯
83
去年
FDA Approves Bimekizumab-bkzx (Bimzelx) for Moderate-to-Severe Hidradenitis Suppurativa
去年
Bimekizumab Gains FDA Approval for Single-Injection Delivery, Expanding Treatment Options
去年
FDA Approves UCB's Bimzelx (bimekizumab-bkzx) for Hidradenitis Suppurativa
去年
FDA Approves Bimzelx (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa
去年
Bimekizumab Shows Sustained Efficacy in Psoriatic Arthritis and Axial Spondyloarthritis in New Two-Year Data
去年
FDA Approves Single-Injection 320 mg BIMZELX® for Plaque Psoriasis and Psoriatic Arthritis
去年
FDA Approves UCB's Bimzelx (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa
去年
Bimekizumab Approved by FDA for Moderate to Severe Hidradenitis Suppurativa
去年
Bimzelx Shows Remarkable Five-Year Efficacy in Moderate-to-Severe Plaque Psoriasis
去年
Bimzelx Approved by FDA as First IL-17A and IL-17F Inhibitor for Hidradenitis Suppurativa
第 1 页,共 9 页
上一页
下一页